Chandan Healthcare Limited, who are listed on the NSE under the ticker CHANDAN, has officially announced a substantial corporate restructuring initiative to focus on its main operating activities. As one of the foremost healthcare and diagnostic services providers based in Lucknow, Uttar Pradesh, the company has approved the divestment of its full equity in Chandan Pharmacy Limited.

The strategic move is designed to strengthen the company’s focus on expanding its primary diagnostic service, which has much higher profit margins than conventional retail pharmacies.

Core strategic benefits and financial terms

The acquisition of Chandan Healthcare Limited resulted in the removal of the entire holding of Chandan Healthcare Limited from the Chloropharm group’s balance sheet, thereby curtailing and rationalising the group’s overall asset performance. The decision represents a conscious shift toward a higher-end product line with more favorable financial attributes, enabling executive management to focus key managerial resources and capital on growth areas like those within pathology and radiology.

The Board of Directors of Chandan Healthcare Limited has voted in favor of the complete divestment of its equity stake in Chandan Pharmacy Limited, which holds a 53.56% stake. The total stake is being given to Chandan Hospital Limited, with an aggregate cash consideration to the extent of ₹16.77 crore. This valuation directly aligns with an independent valuation report of Chandan Pharmacy Limited conducted on its equity, which was valued at approximately ₹31.31 crore.

Once this transaction has been completed, Chandan Pharmacy Limited is to be converted into a wholly separate legal entity from Chandan Healthcare Limited. This deconsolidation effectively unites the retail pharmacy business within a narrowed-down organizational structure comprising only diagnostic service delivery and growth.

The divestment provides several immediate strategic benefits for Chandan Healthcare Limited as it will substantially improve the company’s overall margin profile. The deconsolidation of Chandan Pharmacy Limited will eliminate the dilutive effect on consolidated earnings since retail pharmacy operations generally generate narrower margins. Future consolidated financial results and performance metrics will be more representative of the underlying profitability of the core diagnostic division.

The transaction allows effective capital reallocation to the higher return opportunities. The proceeds of the 53.56% stake sale will be used directly for the company’s diagnostic infrastructure. This reallocation of capital from a low-margin retail presence to higher EBITDA diagnostic assets will enable Chandan Healthcare Limited to establish new centres, introduce cutting-edge diagnostic technologies, and optimize operations across its platforms.

Apart from financial benefits, the merger also streamlines the corporate framework of Chandan Healthcare Limited, making it easier for investors and analysts to observe the scope, development, and profitability of the company’s diagnostic services. This improved level of corporate transparency allows for more direct and relevant comparison to specialized diagnostic peers in the Indian healthcare market.

Operational footprint and financial performance

Chandan Healthcare Limited, in its drive to transform into a comprehensive, technology-driven diagnostics platform, is doubling down on its complete divestment of Chandan Pharmacy Limited. Management plans to increase the focus of executives on expanding the overall diagnostic footprint and dedicated investment in the same in the coming years. In addition, new testing centers were opened to improve equipment usage rates, and high-end imaging and laboratory services were extended to representative regional markets.

The variety of the company’s diagnostics includes more than 500 radiological investigations and more than 3,000 pathological investigations. They include routine services like blood investigation, X-ray, ECG, ultrasonography, and advanced diagnostic technologies such as CT scan and MRI imaging. An increased capacity in these niche modalities enables the firm to meet the growing demand for preventative healthcare and advanced disease screenings.

Chandan Healthcare Limited, founded in 2003 as one of the key institutions of the Chandan Group, has expanded its footprint through a network of diagnostic facilities. The company currently runs a strong network of 327 diagnostic centres in India as of June 30, 2026. It is a wide network comprising 264 active franchise stores and offers fast market coverage in urban, semi-urban, and developing regional areas.

The company is equipped with NABL and NABH accredited pathology labs and radiology centers to guarantee strict clinical compliance and diagnostic accuracy. The company’s business model is balanced, with operations in both the B2C retail walk-in patient segment, the B2B institutional and corporate segment and the B2G public-private partnership contracts with various government entities. Such a multilevel system ensures steady income generation and growth possibilities.

The company achieved another landmark in its corporate journey when it got listed in the NSE Emerge segment on February 17, 2025. Performance of the company during FY26 is an indication of a solid base and a Total Income of ₹280.67 crore. During the same financial year, the business reported EBITDA at ₹56.84 crore with PAT at ₹27.06 crore.

The results of this provide further evidence of the strength and earning power of the business. As Chandan Healthcare Limited lowers its pharmacy margin and devotes its capital to diagnostics, the company is now better positioned in terms of both strategic direction and financial health to move into the next phase of its growth.

Conclusion

The selling of Chandan Healthcare Limited’s 53.56% shares in Chandan Pharmacy Limited signifies a significant change in the long-term business strategy of the firm. With the sale of the lower-margin retail pharmacy service, the firm will be able to streamline itself, increase profitability, and focus on execution strategy.

Chandan Healthcare Limited is set to gain high margins from the diagnostic segment in India because of the extensive presence of 327 diagnostic centres and accredited laboratories, along with robust performance in FY26.